Is It Effective? Creatine has long been a popular supplement for athletes and bodybuilders who want to boost muscle strength ...
Health Canada approved AGAMREE for the treatment of Duchenne muscular dystrophy in patients aged 4 years and older; This approval makes AGAMREE the first and only approved therapy ...
For boys who start corticosteroids for DMD, being taller is tied with slower growth, and being older is tied to more weight ...
The FDA re-approved Wellcovorin, a drug from GSK, that the company stopped selling more than 25 years ago, as part of a push from the Trump administration to identify the causes of and potential ...
Investor's Business Daily on MSN
Scholar Rock, A Top 10% Stock, Reverses Higher Despite A Surprise Setback
Shares of Scholar Rock reversed and closed in the green Tuesday after the FDA rejected the company's spinal muscular atrophy drug.
Our annual healthcare roundtable sizes up the risks and opportunities as public policy shifts. 16 stocks to buy now.
Centrally acting agents like phentermine/topiramate and naltrexone/bupropion aid weight reduction but lack MASLD-specific ...
SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation ...
Social determinants of health disproportionately impact patients' ability to maintain and achieve their weight loss goals.
Duchenne muscular dystrophy (DMD) follows an X-linked inheritance pattern. The condition most often affects males, while females may be carriers of the genetic change that causes it. If you have DMD, ...
Martin Whyte does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...
Share on Pinterest Two new studies found that higher doses of semaglutide safely led to greater weight loss with minimal side effects. Olena Malik/Getty Images Researchers say higher doses of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results